These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16166020)

  • 1. Some biological correlates of drug resistance in schizophrenia: a multidimensional approach.
    Altamura AC; Bassetti R; Cattaneo E; Vismara S
    World J Biol Psychiatry; 2005; 6 Suppl 2():23-30. PubMed ID: 16166020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
    Howes OD; Egerton A; Allan V; McGuire P; Stokes P; Kapur S
    Curr Pharm Des; 2009; 15(22):2550-9. PubMed ID: 19689327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance.
    Altamura AC
    Schizophr Res; 1993 Jan; 8(3):187-98. PubMed ID: 8094628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What do ERPs and ERFs reveal about the effect of antipsychotic treatment on cognition in schizophrenia?
    Korostenskaja M; Kähkönen S
    Curr Pharm Des; 2009; 15(22):2573-93. PubMed ID: 19689329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of psychotropic drug response.
    Malhotra AK; Murphy GM; Kennedy JL
    Am J Psychiatry; 2004 May; 161(5):780-96. PubMed ID: 15121641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological determinants of difficult to treat patients with schizophrenia.
    Sharma T; Kerwin R
    Br J Psychiatry Suppl; 1996 Dec; (31):5-9. PubMed ID: 8968649
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacogenetics of antipsychoatics.
    Ozaki N
    Nagoya J Med Sci; 2004 May; 67(1-2):1-7. PubMed ID: 15279062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography and single photon emission CT molecular imaging in schizophrenia.
    Erritzoe D; Talbot P; Frankle WG; Abi-Dargham A
    Neuroimaging Clin N Am; 2003 Nov; 13(4):817-32. PubMed ID: 15024964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments in PET scan imaging of neuroreceptors in schizophrenia.
    Sedvall G; Pauli S; Farde L; Karlsson P; Nyberg S; Nordström AL
    Isr J Psychiatry Relat Sci; 1995; 32(1):22-9. PubMed ID: 7622344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of longitudinal functional neuroimaging studies of drug treatments in patients with schizophrenia.
    Davis CE; Jeste DV; Eyler LT
    Schizophr Res; 2005 Oct; 78(1):45-60. PubMed ID: 15979287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics.
    Nnadi CU; Malhotra AK
    Curr Psychiatry Rep; 2007 Aug; 9(4):313-8. PubMed ID: 17880863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response.
    Nyberg S; Nakashima Y; Nordström AL; Halldin C; Farde L
    Br J Psychiatry Suppl; 1996 May; (29):40-4. PubMed ID: 8733822
    [No Abstract]   [Full Text] [Related]  

  • 14. Magnetic resonance imaging and single photon emission tomography in treatment-responsive and treatment-resistant schizophrenia.
    Lawrie SM; Ingle GT; Santosh CG; Rogers AC; Rimmington JE; Naidu KP; Best JJ; O'Carroll Re; Goodwin GM; Ebmeier KP
    Br J Psychiatry; 1995 Aug; 167(2):202-10. PubMed ID: 7582670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
    Stahl SM; Shayegan DK
    J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of PET imaging in studying cognition, genetics and pharmacotherapeutic interventions in schizophrenia.
    Vyas NS; Patel NH; Nijran KS; Al-Nahhas A; Puri BK
    Expert Rev Neurother; 2011 Jan; 11(1):37-51. PubMed ID: 21158554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Genetic and pharmacological effects on prefrontal cortical function in schizophrenia].
    Heinz A; Braus DF; Romero B; Gallinat J; Puls I; Juckel G; Weinberger DR
    Nervenarzt; 2004 Sep; 75(9):845-56. PubMed ID: 15372159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutamatergic agents for schizophrenia: current evidence and perspectives.
    Zink M; Correll CU
    Expert Rev Clin Pharmacol; 2015 May; 8(3):335-52. PubMed ID: 25916667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].
    Guise S; Soubrouillard C; Blin O
    Encephale; 1997 Apr; 23 Spec No 2():10-6. PubMed ID: 9273300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics.
    Tyson PJ; Laws KR; Flowers KA; Tyson A; Mortimer AM
    Psychiatry Clin Neurosci; 2006 Aug; 60(4):473-9. PubMed ID: 16884450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.